A validated pediatric disease risk index for allogeneic hematopoietic cell transplantation
| Autor: | Wing Leung, Muna Qayed, Brandon M. Triplett, Joseph H. Chewning, Kwang Woo Ahn, Jacek Toporski, Karin Mellgren, Christopher C. Dvorak, Brian D. Friend, Alan S. Wayne, Carrie L. Kitko, Michael R. Verneris, Gregory A. Yanik, Mariam H Johnson, Mary Eapen, Nirali N. Shah, John E. Levine, Urvi Kapoor, Kirk R. Schultz |
|---|---|
| Rok vydání: | 2020 |
| Předmět: |
Oncology
Male medicine.medical_specialty Neoplasm Residual Adolescent medicine.medical_treatment Immunology Hematopoietic stem cell transplantation Kaplan-Meier Estimate Biochemistry Pediatric Disease Risk Assessment Severity of Illness Index Disease-Free Survival Cohort Studies Random Allocation Risk groups Risk Factors Internal medicine Risk index Antineoplastic Combined Chemotherapy Protocols medicine Hematologic malignancy Humans Child Hematopoietic cell business.industry Age Factors Hematopoietic Stem Cell Transplantation Infant Cell Biology Hematology Precursor Cell Lymphoblastic Leukemia-Lymphoma medicine.disease Allografts Prognosis Combined Modality Therapy Transplantation Leukemia Leukemia Myeloid Acute Child Preschool Female business |
| Zdroj: | Blood. 137(7) |
| ISSN: | 1528-0020 |
| Popis: | A disease risk index (DRI) that was developed for adults with hematologic malignancy who were undergoing hematopoietic cell transplantation is also being used to stratify children and adolescents by disease risk. Therefore, to develop and validate a DRI that can be used to stratify those with AML and ALL by their disease risk, we analyzed 2569 patients aged 8) risk groups was 78%, 53%, 40%, and 25%, respectively (P < .0001). For ALL, 3 risk groups were identified based on age and disease status, including minimal residual disease status at transplantation. The 5-year leukemia-free survival for low (0 points), intermediate (2-4), and high (≥5) risk groups was 68%, 51%, and 33%, respectively (P < .0001). We confirmed that the risk groups could be applied to overall survival, with 5-year survival ranging from 80% to 33% and 73% to 42% for AML and ALL, respectively (P < .0001). This validated pediatric DRI, which includes age and residual disease status, can be used to facilitate prognostication and stratification of children with AML and ALL for allogeneic transplantation. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|